ClinConnect ClinConnect Logo
Search / Trial NCT02544347

Gingival Crevicular Fluid Vaspin and Omentin Levels in Type 2 Diabetic Patients With Chronic Periodontitis

Launched by BULENT ECEVIT UNIVERSITY · Sep 8, 2015

Trial Information

Current as of July 25, 2025

Completed

Keywords

Vaspin Omentin Diabetes Mellitus Chronic Periodontitis Tumor Necrosis Factor Alfa Gingival Crevicular Fluid

ClinConnect Summary

Adipose tissue produces and releases a variety of inflammatory factors, including adipocytokines , such as adiponectin, leptin, tumor-necrosis factor alpha (TNF-α), interleukin-6 (IL-6), visfatin, vaspin and omentin.These adipokines have widespread effects on carbohydrate and lipid metabolism and appear to play an important role in the pathogenesis of insulin resistance, diabetes, inflammation, wound healing, and immune responses.Recently, studies evaluated the serum vaspin and omentin levels as inflammatory markers in T2DM patients. Based on the above mentioned studies, the present investi...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Diabetic subjects should have T2DM and had no any known systemic diseases other than T2DM
  • Subjects who had HbA1c levels \< 8% and ≥ 6.5% (well and moderate control)
  • Chronic periodontitis patients had radiographic evidence of bone loss and attachment loss with a minimum of 6 teeth having pocket probing depth (PD) ≥ 5mm in at least 2 different quadrants
  • Control groups were designed as healthy if the full-mouth probing depth (PD) was ≤3mm and bleeding on probing (BOP) score \< %15 at examination and they had no radiographic evidence of alveolar bone loss.
  • Exclusion Criteria:
  • Presence of other systemic disorders that could influence the course of periodontal disease; pregnancy, lactation, current and former use of tobacco;
  • Administration of non-steroidal and anti-inflammatory drugs or antibiotic therapies within the previous 6 months;
  • Need for antibiotic prophylaxis for dental treatment and having received non-surgical periodontal treatment within the past 6 months or surgical periodontal treatment within the past 12 months.
  • Subjects who had body mass index (BMI) \>24.9 kg /m2

About Bulent Ecevit University

Bülent Ecevit University is a distinguished academic institution located in Zonguldak, Turkey, committed to advancing medical research and innovation. As a clinical trial sponsor, the university leverages its robust academic resources and interdisciplinary expertise to conduct high-quality research aimed at improving patient care and healthcare outcomes. The institution fosters collaboration among researchers, clinicians, and industry partners, ensuring adherence to ethical standards and regulatory compliance while promoting the translation of scientific discoveries into practical applications. Through its clinical trials, Bülent Ecevit University strives to contribute valuable insights to the medical community and enhance the overall health landscape.

Locations

Patients applied

0 patients applied

Trial Officials

Umut Ballı, DDS

Principal Investigator

Bülent Ecevit University Faculty of Dentistry

Şeyma Bozkurt Doğan, DDS

Study Chair

Bülent Ecevit University Faculty of Dentistry

Figen Öngöz Dede, DDS

Principal Investigator

Bülent Ecevit University Faculty of Dentistry

Erdim Sertoğlu, MD, DDS

Principal Investigator

Gülhane Military Medical Academy

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials